Safety & Efficacy Study of quetiapine fumarate (SEROQUEL®) vs. placebo in Major Depressive Disorder - MOONSTONE

Study identifier:D1448C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-release (SEROQUEL®) as Monotherapy in the Treatment of Patients with MDD

Medical condition

Major depressive disorder

Phase

Phase 3

Healthy volunteers

No

Study drug

Quetiapine fumarate

Sex

All

Actual Enrollment

600

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Apr 2006
Primary Completion Date: -
Study Completion Date: 01 May 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria